Melissa is an associate in the Firm's Capital Markets practice in New York. Melissa represents clients in securities transactions and corporate governance matters. She also represents clients in SPAC transactions. Melissa has represented SPACs from their initial public offering through their de-SPAC mergers.
Representation of Inflection Point Acquisition Corp. II, a Cayman Islands exempted SPAC, on its US$250 million initial public offering of units.
Representation of Biosynex S.A., a French biotechnology société anonyme, on its US$0.45/share acquisition of Chembio Diagnostics, Inc., a U.S. biotechnology corporation.
Representation of Falcon's Beyond Global, LLC, a leading fully integrated global entertainment development company specializing in intellectual property creation and expansion, in its merger with FAST Acquisition Corp. II (NYSE: FZT), a SPAC. Upon completion of the proposed business combination, the new combined company will change its name to "Falcon's Beyond Global" and is expected to be listed on Nasdaq under the ticker symbol "FBYD."
Represented Artemis Strategic Investment Corporation (Nasdaq: ARTE), a SPAC, in its US$625 million business combination with Logflex MT Holding Limited (doing business as "Novibet"), an established and profitable technology-enabled operator of iGaming and online sports betting.
Represented Helix Acquisition Corp. (Nasdaq: HLXA), a SPAC, in its US$230 million business combination with MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases.
Represented B. Riley Principal 150 Merger Corp. (Nasdaq: BRPM), a SPAC, in its US$1 billion business combination with FaZe Clan, Inc., a leading US gaming, lifestyle and digital content platform.